行情

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

实时行情|Nasdaq Last Sale

8.07
+0.67
+9.05%
交易中 14:30 09/21 EDT
开盘
7.61
昨收
7.40
最高
8.29
最低
7.46
成交量
41.26万
成交额
--
52周最高
13.18
52周最低
5.70
市值
1.72亿
市盈率(TTM)
-6.2187
分时
5日
1月
3月
1年
5年
Actinium 将出席四场即将举行的投资者会议
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will present at four upcoming investor conferences.
PR Newswire · 1天前
从周五开始的 48 个最大的推动者
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
Benzinga · 1天前
为什么 Actinium Pharmaceuticals 的股票今天交易更高
Actinium Pharmaceuticals (AMEX:ATNM) shares are trading higher after the company announced it completed enrollment in the pivotal Phase 3 SIERRA trial of iomab-B.
Benzinga · 5天前
YY、NNVC 和 REKR 处于午盘走势中
Gainers: GreenSky (NASDAQ:GSKY) +53%. IronNet (NYSE:IRNT) +27%. Sphere (NASDAQ:ANY) +22%. Allied Healthcare Products (NASDAQ:AHPI) +19%. Actinium Pharmaceuticals (NYSE:ATNM) +16%. Ampio Pharmaceuticals (NYSE:AMPE) +15%. Inozyme Pharma (NASDAQ:INZY) +15%. S...
Seekingalpha · 6天前
38 只股票在周三的午盘交易中移动
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company's platform technology.
Benzinga · 6天前
CTXS、ATNM 和 GSKY 是盘前赢家
GreenSky (NASDAQ:GSKY) +48% Goldman Sachs to acquire GreenSky Birks Group (NYSE:BGI) +13%. Innate Pharma (NASDAQ:IPHA) +12% on 1H earnings. LM Funding America (NASDAQ:LMFA) +12% expands into cryptocurrency mining business MeaTech 3D (NASDAQ:MITC) +11% manu...
Seekingalpha · 6天前
BRIEF-Actinium 完成了 Iomab-B 关键阶段 3 Sierra 试验的注册
reuters.com · 6天前
Actinium 完成了 Iomab-B 关键 3 期 SIERRA 试验的注册
/PRNewswire/ --   (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that it has completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamistamab, a CD45 targeting antibod...
PR Newswire - PRF · 6天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ATNM最新的财务预测,通过ATNM每股收益,每股净资产,每股现金流等数据分析ACTINIUM PHARMAC近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ATNM价格均价为32.50,最高价位45.00,最低价为20.00。
EPS
机构持股
总机构数: 42
机构持股: 2,339.65万
持股比例: 109.68%
总股本: 2,133.13万
类型机构数股数
增持
10
554.20万
建仓
5
1,091.19万
减持
6
158.86万
平仓
5
30.64万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.31%
制药与医学研究
+0.75%
高管信息
Chairman/Chief Executive Officer/Director
Sandesh Seth
Chief Financial Officer
Steve O'Loughlin
Chief Technology Officer/Chief Scientific Officer
Dale Ludwig
Other
Mark Berger
Lead Director/Independent Director
C. David Nicholson
Independent Director
Jeffrey Chell
Independent Director
Ajit Shetty
Independent Director
Richard Steinhart
暂无数据
ATNM 简况
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

微牛提供Actinium Pharmaceuticals Inc(AMEX-ATNM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ATNM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ATNM股票基本功能。